Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
42.2M
-
Number of holders
-
39
-
Total 13F shares, excl. options
-
12.8M
-
Shares change
-
+12.8M
-
Total reported value, excl. options
-
$524M
-
Value change
-
+$524M
-
Number of buys
-
39
-
Price
-
$41.33
Significant Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) as of Q4 2020
39 filings reported holding TARS - Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q4 2020.
Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) has 39 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.8M shares
of 42.2M outstanding shares and own 30.24% of the company stock.
Largest 10 shareholders include Vivo Capital, LLC (3.25M shares), RTW INVESTMENTS, LP (2.46M shares), FRAZIER MANAGEMENT LLC (1.92M shares), Cormorant Asset Management, LP (1.71M shares), PERCEPTIVE ADVISORS LLC (1.3M shares), TimesSquare Capital Management, LLC (465K shares), BlackRock Inc. (322K shares), VANGUARD GROUP INC (271K shares), SANDS CAPITAL MANAGEMENT, LLC (260K shares), and Ensign Peak Advisors, Inc (200K shares).
This table shows the top 39 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.